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612 The Journal of Thoracic and Cardbjective: Allosensitization of left ventricular assist device recipients has been
ssociated with perioperative transfusion of cellular blood products. The relative
ensitizing contribution of leukofiltered cellular blood products, however, re-
ains unclear. We investigated the pattern of sensitization in left ventricular
ssist device recipients in relation to cellular blood product transfusions re-
eived.
ethods: Seventy-one consecutive nonsensitized recipients of the HeartMate left
entricular assist device (Thoratec Corporation, Pleasanton, Calif) as a bridge to
ransplantation were reviewed. Panel-reactive HLA antibody levels at consec-
tive times after device implantation were correlated with perioperative cellular
lood product transfusions.
esults: Fifty-four patients received leukofiltered cellular blood products (trans-
used), whereas 17 patients received only fresh-frozen plasma (nontransfused).
mong nontransfused patients, 58.8% (10/17) became sensitized during me-
hanical support, versus 35.2% of transfused patients (19/54, P  .15). There
as a trend toward more sensitization during the 12 weeks after device place-
ent in nontransfused patients. Kaplan–Meier analysis revealed significantly
ore sensitization in nontransfused patients than in transfused patients, despite
qual rates of transplantation (P  .05). A dose-response analysis revealed
ignificant trends toward less sensitization and lower peak panel-reactive anti-
ody level with more cellular blood product transfusions (P  .04). Multivariate
ox regression revealed only increasing transfusions to be associated with a
educed risk of sensitization (hazard ratio 0.18, P  .01).
onclusions: Sensitization becomes more prevalent with increasing length of
upport. Avoidance of perioperative leukocyte-filtered cellular blood product
ransfusions does not decrease the incidence or degree of HLA sensitization.
onversely, cellular blood product transfusions may be associated with lessened
lloimmunization and may mitigate the sensitization seen in recipients of the
eartMate left ventricular assist device as a bridge to transplantation.
iovascular Surgery ● June 2007
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TXhe advent of mechanical assistance for the failing left
ventricle has been lifesaving for patients awaiting
heart transplantation. As the number of patients
isted for transplantation has risen in an era of fixed or
eclining donor availability, many have required mechani-
al ventricular assistance as a bridge to transplantation.
ince approval for clinical use, left ventricular assist devices
LVADs) have contributed to the progressive decline in
eath rate on the United Network for Organ Sharing heart
ransplant waiting list, which has decreased from 274 to 162
eaths per 1000 patient-years at risk in the period from 1994
o 2003.1 LVADs have allowed many patients to survive
uccessful transplantation who otherwise would have either
ied or become unsuitable transplant candidates.2
Despite this success in bridging strategy, it has become
pparent that many LVAD-supported heart transplant can-
idates have circulating anti-HLA antibodies develop, with
otential donor reactivity, and show elevation of panel-
eactive antibody (PRA).3,4 The existence of preforme
ntibodies delays cardiac transplantation, decreases the po-
ential donor pool because of difficulty in identifying a
uitable crossmatch-negative donor, and can exact a signif-
cant emotional toll on patients as the wait for a compatible
onor goes on and on. Furthermore, sensitized patients have
een shown to be at higher risk for posttransplantation
ejection, morbidity, and mortality.5-7
Patients who require mechanical support often receive
ultiple transfusions because of coagulopathy from hepatic
ongestion or poor hepatic function, bleeding caused by
dhesions from previous surgery, or preoperative anticoag-
lation. Sensitization of the LVAD recipient has been
hought to be associated with the perioperative transfusion
f cellular blood products, which are often required.3,4,8 We
ave had success in limiting or completely avoiding the
mount of cellular blood products transfused in this patient
opulation.9 In this study we investigated the relative c-
ribution of cellular blood product transfusion to HLA
llosensitization in LVAD recipients bridged to cardiac
ransplantation.
aterials and Methods
he clinical and laboratory records were reviewed for 84 consec-
tive patients with heart failure who underwent implantation of
ither the IP (pneumatic) or VE (vented electric) HeartMate LVAS
Thoratec Corporation, Pleasanton, Calif) as a bridge to transplan-
ation from May 30, 1993, to August 6, 2002. All patients provided
nformed consent for collection of data used in this study, and the
nstitutional review committee from each institution approved such
ata collection for research. Serum samples from each patient were
ollected before LVAD implantation and at intervals of 2 to 4
eeks thereafter; samples underwent PRA determination against a
anel of donor lymphocytes representing the spectrum of HLA
pecificities by either the antiglobulin-augmented, complement-
ependent lymphocytotoxicity assay or flow cytometry, methods
hat were used with equal frequency and found to be comparable w
The Journal of Thoracicn detecting HLA antibody.9 All samples were treated with dith-
hreitol to remove immunoglobulin M sensitivity. A PRA greater
han 10%, indicating antibody reactive against antigen in10% of
ested samples, was accepted as defining HLA allosensitization.
ll sensitized LVAD recipients underwent a negative prospective
rossmatch before transplantation. PRA levels indicating the de-
ree of sensitization were correlated with perioperative transfu-
ions of cellular blood products, defined as either packed red blood
ells (pRBCs) or platelets. The perioperative period was defined
rom LVAD implantation to 4 weeks after implantation.
Thirteen patients found to have either an elevated PRA (10%,
 10) or no PRA measurement before LVAD implantation (n 
) were excluded from further analysis. This report consists of
nalysis of the remaining 71 patients. The transfused group (n 
4) comprised patients receiving perioperative cellular blood prod-
cts. The nontransfused group (n 17) did not receive any cellular
lood products. All in the nontransfused group, however, did
eceive perioperative fresh-frozen plasma (FFP). All cellular blood
roducts were leukocyte filtered with standard, commercially
vailable filters. Indications for transfusion included a hematocrit
ower than 25% for pRBCs or continued bleeding with a platelet
ount lower than 100,000 cells/L for platelets. In the nontrans-
used group, patients were given FFP to correct coagulopathy and
llowed to have a lower hematocrit if right ventricular function
emained adequate and mixed venous oxygen saturation remained
bove 60%, as per our previously published protocol.9
Results of continuous variables are expressed as the mean 
D. Comparisons between the two groups were made with the 2
est, Fisher exact test, and Student t test. Rates of sensitization and
ransplantation across time were determined by Kaplan–Meier
ethods and compared with the log–rank test. The effect of
ransfusion quantity on sensitization was determined by dividing
he entire patient population into four equal quartiles according to
he combined number of units of cellular blood products (either
RBCs or platelets) received. The first quartile (Q1) included 17
atients who received no cellular blood products. The second
uartile (Q2) received 1 to 6 units of cellular blood products (n 
8), the third quartile (Q3) received 7 to 15 units (n 18), and the
ourth quartile (Q4) received 16 or more units (n  18). Differ-
nces in PRA across quartiles were assessed with the Kruskal–
allis test, and differences between individual quartiles were
valuated by the Wilcoxon–Mann–Whitney test. Comparisons
Abbreviations and Acronyms
CI  confidence interval
FFP  fresh-frozen plasma
HR  hazard ratio
LVAD  left ventricular assist device
PRA  panel-reactive antibody
pRBCs packed red blood cells
Q1  first quartile
Q2  second quartile
Q3  third quartile
Q4  fourth quartileere also performed for categories of peak PRA, sensitized
and Cardiovascular Surgery ● Volume 133, Number 6 1613
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1
TX10%), and highly sensitized (90%) according to transfusion
uartile with the 2 statistic and the Armitage test for linear trend.
Univariate and multivariate Cox regression analyses were used
o assess the impact of patient-related and transfusion-related vari-
bles on the risk of sensitization, with censoring of time-related
vents such as death or transplantation. Conditional stepwise and
orced variable entry was used to assess confounding and model
t. Variables included patient age, duration of support, previous
ternotomy, heart failure etiology, and quartile of either combined
ransfusion quantity or separate component quantity. Age was
odeled as a continuous variable. Separate component quartiles
ere defined for pRBCs (Q1 0 units, n  18, Q2 1–5 units, n 
5, Q3 6–13 units, n  19, Q4  14 units, n  19), platelets (Q1
units, n  28, Q2 1 unit, n  11, Q3 2–4 units, n  16, Q4 
units), and FFP (Q1  6 units, n  21, Q2 7–12 units, n  14,
3 13–16 units, n  20, Q4  17 units, n  16).
esults
he transfusion requirements and demographic characteris-
ics of each group are summarized in Table 1. Of t
atients studied, 54 received cellular blood products (trans-
used group); the remaining 17 received no cellular blood
roducts (nontransfused group). All patients in the non-
ransfused group and all but 4 patients in the transfused
roup received perioperative transfusions of FFP. The age,
ex, cardiac diagnosis, duration of mechanical support,
aiting time to transplantation, survival to transplantation,
ncidence of previous sternotomy, and preimplantation total
ilirubin as a marker of heart failure severity were similar
etween groups.
During the wait for transplantation, there was a trend
oward less overall sensitization in the transfused group,
lthough this did not reach statistical significance. In the
ABLE 1. Patient characteristics
Cellular transfusion
ransfusion requirements
Fresh-frozen plasma (units) 12.5 8.0 (0–
Packed red blood cells (units) 10.9 10.0 (0
Platelets (units) 3.3 3.3 (0–
ge (y) 50.2 11.1
ardiac diagnosis (No.)
Idiopathic dilated cardiomypathy 15
Coronary artery disease 35
Other 4
ex (male/female) 49:5
uration of support (d) 181.6 171.2
ime to transplantation (d) 178.9 182.8
urvival to transplantation (No.) 50/54 (92.6%
revious median sternotomy (No.) 18/54 (33.3%
re-LVAD total bilirubin (mg/dL) 1.8 1.5
VAD replacements (No.) 5/54 (9.3%
ata represent mean  SD (with ranges in parentheses as appropriate)ransfused group 35.2% of patients (19/54) became sensi- (
614 The Journal of Thoracic and Cardiovascular Surgery ● Jun1
ized (PRA 10%) during mechanical support, compared
ith 58.8% (10/17) in the nontransfused group (P .15). A
RA greater than 90% was seen in 16.7% patients (9/54) in
he transfused group versus 23.5% patients (4/17) in the
ontransfused group (P  .5).
A similar trend was seen in the mean PRA at consec-
tive time points after LVAD implantation (Figure 
he transfused group had mean PRAs of 7.9%  22%
n  51), 10.9%  24.5% (n  40), 16.9%  29.8% (n 
3), and 24.6%  36.9% (n  34) at 4, 6, 8, and 12
eeks after implantation, respectively. The nontrans-
used group had mean PRAs of 8.5%  17.7% (n  15),
6%  29.6% (n  11), 35.1%  39.1% (n  12), and
igure 1. Time course of development of sensitization (panel
eactive antibody [PRA] >10%) after left ventricular assist device
54) No cellular transfusion (n  17) P value
9.9 5.1 (4–19)
48.8  15.8 .69
7 .46
9 .32
1 .999
16:1 .999
166.7  155.3 .75
163.9  167.1 .77
16/17 (94.1%) .999
6/17 (35.3%) .999
1.6  1.1 .65
3/17 (17.6%) .39
t as noted. LVAD, Left ventricular assist device.(n 
34)
–45)
12)
)
)
)LVAD) implantation.
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TX7.6%  37.5% (n  9) at 4, 6, 8, and 12 weeks after
mplantation, respectively (difference not significant). There
as no difference between the peak PRA reached in the
ransfused group and that in the nontransfused group
66.7%  31.7% transfused vs 71.1%  24.3% nontrans-
used, P  .70).
Among patients becoming sensitized, there was a trend
oward earlier sensitization with transfusions (5.4  3.2
igure 2. Kaplan–Meier analysis of incidence of sensitization
mong left ventricular assist device (LVAD) recipients who either
id or did not receive cellular blood product transfusions.
igure 3. Kaplan–Meier analysis of incidence of transplantation
mong left ventricular assist device (LVAD) recipients who either
id or did not receive cellular blood product transfusions. t
The Journal of Thoraciceeks in the transfused group vs. 8.4 4.3 weeks in the
ontransfused group, P  .08), as well as an earlier peak
RA in patients receiving transfusions (12.1  7.9 weeks
ransfused vs 16.8  8.8 weeks nontransfused, P  .16).
When the groups were analyzed by Kaplan–Meier
ethods for freedom from sensitization, a larger propor-
ion of the nontransfused group became sensitized during
upport relative to the transfused group, reaching signif-
cance 3 months after LVAD implantation (P  .05,
igure 2). This result could be skewed by the ra
ransplantation, because the actuarial analysis censored
atients not only for sensitization but also for transplanta-
ion (because after transplantation patients were no longer
onsidered at risk). Theoretically, if more patients in a
articular group underwent transplantation early, before be-
oming sensitized, that group would eventually show a
arger percentage of sensitized patients still waiting for
ransplantation. To help avoid this confusion, we compared
he rate of transplantation between the two groups and
ound it to be nearly identical (Figure 3). When the r
ransplantation was compared between sensitized and non-
ensitized patients, however, there was a significant delay in
ransplantation for those with PRA greater than 10% (P 
001; Figure 4).
To elucidate the impact of transfusion quantity on al-
osensitization, the entire patient population was divided
nto equal quartiles according to the combined units of
ellular blood products received. The proportions of sensi-
ized and highly sensitized (PRA  90%) patients and peak
RAs for each quartile are summarized in Table 2. 
uration of mechanical support was similar among the quar-
iles. The peak PRA of the massively transfused subgroup
igure 4. Kaplan–Meier analysis of rates of transplantation in left
entricular assist device recipients who either did (panel reac-
ive antibody > 10%) or did not acquire allosensitization.
and Cardiovascular Surgery ● Volume 133, Number 6 1615
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1
TXQ4) was significantly lower than the peak PRA in the not
ransfused (Q1) subgroup (P  .02). Differences in peak
RA level of all four quartiles were also found to be
ignificant (P  .02).
Analysis of the proportion of nonsensitized and highly
ensitized patients in each quartile showed a significant
tepwise linear trend (P  .04), suggesting that patients
ith higher transfusion requirements actually had less sen-
itization. Only 41% in the nontransfused group (Q1) re-
ained free of sensitization, compared with 83% of the
assively transfused patients (Q4, P  .009), whereas 18%
f Q1 patients became highly sensitized compared with only
% of those in Q4 (P  .25).
A Cox regression analysis was used to assess the effects
f patient-related and transfusion-related variables on the
isk of sensitization. With univariate analysis, only quartile
f transfusion (Q1 vs Q4, P  .013) was associated with
ensitization. Factors not associated with increased risk of
ensitization included age (P  .69, hazard ratio [HR]
.94/decade, 95% confidence interval [CI] 0.70-1.43), sex
P  .85, HR 0.87, 95% CI 0.21–3.66), duration of support
t least 6 weeks (P  .24, HR 3.39, 95% CI 0.45–2.54),
revious sternotomy (P  .46, HR 0.72, 95% CI 0.30–
.72), and heart failure etiology other than coronary artery
isease (idiopathic P .71, HR0.85, 95% CI0.36–2.03,
ther P  .69, HR 1.35, 95% CI 0.31–5.83). Multivariate
egression (Table 3) confirmed a reduced risk of sensi
ion at each quartile of increasing transfusion.
Analysis of the component-specific effect of blood prod-
cts on sensitization was difficult because of the small
ABLE 2. Effect of cellular transfusion quantity on sensitiz
uartile n Support (d)
uartile 1 (none) 17 166 155
uartile 2 (1–6 units) 18 198 170
uartile 3 (7–15 units) 18 161 192
uartile 4 (16 units) 18 168 156
RA, Panel-reactive antibody. *P  .02, quartile 4 versus quartile 1. †P 
ABLE 3. Multivariate Cox regression analysis of risk of s
Variable H
Combined transfusion quartile (vs quartile 1)
Quartile 2 (1–6 units)
Quartile 3 (7–15 units)
Quartile 4 (16 units)
Individual components (vs quartile 1)
Packed red blood cell quartile 4 (14 units)
Platelets quartile 4 (5 units)
Fresh-frozen plasma quartile 4 (17 units)Statistically significant.
616 The Journal of Thoracic and Cardiovascular Surgery ● Junumbers involved and significant overlap of blood products
sed, making meaningful statistical comparisons difficult.
n the nontransfused group, those becoming sensitized (10/
7, 59%) received a mean of 9.5 units of FFP, whereas those
emaining nonsensitized received a mean of 11.0 units of
FP (difference not significant). Only 2 patients received
RBCs and no FFP or platelets; 1 received 3 units and the
ther 16 units. Both remained nonsensitized at transplanta-
ion 1 and 6 months later, respectively. Eleven patients
eceived pRBCs but no platelets (8 received FFP), and 4
36%) became sensitized. Only 1 patient received platelets
ut no pRBCs and had become sensitized by 6 weeks of
upport. Conversely, 9 patients received 6 or more units of
latelets (as well as multiple units of pRBCs), and only 2
22%) became sensitized.
Multivariate Cox regression analysis examining each
omponent separately in four quartiles according to trans-
usion volume showed the risk of sensitization was lowest
n Q4 versus Q1, with the effect from pRBCs being the
trongest. Because of significant exposure to both pRBCs
nd either platelets or FFP, however, the major benefit may
ave been from exposure to pRBCs (Table 3).
iscussion
ridging to cardiac transplantation with LVAD support has
ecome a widely accepted method of heart failure treatment
or those who would otherwise not survive. Many of these
atients, however, eventually acquire circulating antibody
ith HLA reactivity. There are few data on the true char-
cter of this antibody, except that it is often highly reactive
n
Peak PRA (%)
Nonsensitized
(PRA < 10%)
Highly sensitized
(PRA > 90%)
42% 40% 41% 18%
39% 43% 44% 28%
19% 34% 72% 11%
9% 25%* 83%† 6%
quartile 4 versus quartile 1.
tization
ratio 95% Confidence interval P value
9 0.45–2.63 .85
3 0.15–1.25 .12
8 0.05–0.67 .01*
7 0.05–0.61 .007*
3 0.06–0.79 .020*
5 0.11–1.10 .07atioensi
azard
1.0
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0.1
0.2
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TXn standard HLA class I antibody screens, sometimes reach-
ng 100%. In our experience, rarely is antibody to HLA
lass II antigens observed (unpublished data). Sensitized
VAD recipients may wait years for a compatible donor.
nly limited success has been achieved with protocols of
esensitization,10 which are neither universally successf
or standardized and expose the patient to invasive proce-
ures and costly medications with significant risks and
otential side effects. Furthermore, sensitization has been
mplicated in increasing the risks of acute rejection and
osttransplantation death.5-7
In patients who have not been previously sensitized, the
ajor factor giving rise to antibody production is commonly
hought to be the number of transfusions received at the
ime of LVAD implantation.3,4,8 Leukocytes contained in
ellular blood product transfusions have long been impli-
ated as a source of sensitization. Fauchet and colleague11
howed that after transfusions of nonleukofiltered blood prod-
cts during cardiac surgical procedures, 33.6% of male and
4.3% of female patients acquired anti-HLA antibodie11
ethods of leukofiltration have been more recently adopted to
ecrease the alloimmunizing effect of transfusions. Leukocyte
eduction filters have been shown to decrease the total leuko-
yte count to less than 5 106 per blood component and to be
ffective at reducing the incidence of sensitization in patients
ithout previous exposure.12
In this study, we attempted to characterize the patterns of
nd contributing factors to post-LVAD sensitization when
eukofiltered blood products are used. We found that trans-
usions of leukofiltered cellular blood products did not
orsen sensitization relative to patients who received no
uch transfusions. Unexpectedly, we found a trend toward a
igher rate of sensitization in nontransfused patients and noted
hat nontransfused patients became sensitized more frequently
hen studied across time by actuarial methods. We initially
upposed that this was because more nonsensitized patients in
he nontransfused group underwent transplantation early, thus
liminating nonsensitized patients from the cohort and increas-
ng the relative proportion of sensitized patients. On further
nalysis, however, the rate of transplantation was found to be
dentical between these two groups.
We also paradoxically found lower sensitization among
atients who received more transfusions of cellular blood
roducts, with the lowest incidence occurring among those
eceiving the highest numbers of transfusions. This linear
rend reached significance despite the small numbers of
atients in each quartile. Further analysis by multivariate
ox regression failed to show any significant impact of age,
ex, LVAD support longer than 6 weeks, previous surgery,
r heart failure etiology. Although sensitization increased
ith time, only increasing amounts of cellular blood prod-
ct transfusion were associated with a progressive risk
eduction for sensitization. Examination for a component- F
The Journal of Thoracicpecific effect showed exposure to pRBCs to have the
trongest protective effect against sensitization.
Our findings suggest that strategies of withholding peri-
perative transfusions in LVAD recipients have no clear
dvantage in reducing sensitization as long as leukofiltered
lood products are used. This is not to say, however, that
ransfusion with impunity is acceptable in this population.
ur data do not show that leukofiltered blood products do
ot cause alloimmunization. HLA sensitization may still
ccur as a result of transfusion. Transfusions also have other
dverse sequelae, such as pulmonary dysfunction, increased
isk of right heart failure,13 and increased risk of infection.14
ransfusions should be given judiciously and only when
ecessary.
The counterintuitive hypothesis that transfusion may re-
ult in less sensitization will require more careful study in
arger numbers of patients. It is, however, consistent with
he known immunomodulatory effects of transfusions.15,16
retransplantation transfusions have been suggested as a
eans for improving kidney allograft survival because of
heir immunosuppressive effect.17 Leukofiltration has been
eported to decrease or eliminate this immunosuppressive
ffect.18 Our data suggest that an immunosuppressive eff
f transfusions may still be present even after leukofiltra-
ion, although larger numbers of leukofiltered cellular blood
roducts may be necessary to limit sensitization. Perhaps
his may occur through a critical mass of leukocytes that
scape filtration and are passed on to the recipient. At least
ne report has suggested a decreased rate of rejection with
ncreasing amounts of transfusion in heart transplant recip-
ents previously supported by LVADs.19
Interpretation of results from this retrospective study
ay be difficult for several reasons. Other studies have
uggested that sharing of an HLA-DR locus between blood
onor and recipient may limit the sensitizing effect and
mplify the immunosuppressive effect of transfusion.20 Un-
ortunately, HLA typing of all blood donors was not avail-
ble for this study. Other theories suggest that the timing of
ransfusion is important. Transfusions given intraopera-
ively, when stress hormones and cytokines are maximal,
ay be more immunogenic than transfusions given during
ytokine quiescence.21 This heterogeneous population als
ncludes some debilitated patients who may not be capable
f generating an immunologic response at the time of LVAD
lacement, further confusing the picture. Our attempt to con-
rol for the degree of illness with serum bilirubin, a marker of
epatic congestion and long-standing heart failure, showed no
ifference between groups. Serum bilirubin is a nonspecific
arker, however, and may have poor correlation with such
n anergic state. Clarification of these issues may not be
orthcoming until the true nature, specificity, and time
ourse of the generated antibody have been characterized.
urther study of methods to reduce sensitization will likely
and Cardiovascular Surgery ● Volume 133, Number 6 1617
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1
TXequire a prospective approach that can control for these
ariables. Unfortunately, controlled, prospective trials of
his nature would be extremely difficult to perform and may
ot ever be realistically achieved.
Because this study suggests that sensitization is not
orsened by transfusions, the true source of stimulation of
ntibody production remains in question. Sensitization in
VAD recipients may occur as a result of passenger leuko-
ytes that escape filtration, cytokine activation, or immuno-
enic stimuli from the pump itself. Antibody stimulated by
ther sources and cross-reactive to HLA epitopes is known
o occur.22 FFP, which was received by most patients in
tudy, may also contain small concentrations of soluble
LA antigen and could have a weak immunizing effe23
tescu and colleagues24 have reported that activated inflam-
atory cells within the pseudoneointima of the HeartMate
extured pumping chamber surface demonstrate augmented
xpression of the inflammatory mediator nuclear factor B
nd may give rise to increased production of inflammatory
ytokines and B-cell hyperreactivity.24 This textured sur-
ace has been shown to colonize with pluripotent hemato-
oietic stem cells, which also could become immunologi-
ally active.25 Schuster and associates26 have suggested tha
xposure of human mononuclear cells to LVAD-derived
iomaterial leads to T-cell–dependent B-cell activation
hrough a CD40-CD40 ligand interaction and that treatment
ith calcineurin inhibitors or monoclonal antibodies against
ither CD25 or CD40 ligand could be effective at prevent-
ng B-cell hyperreactivity and allosensitization. Baran and
olleagues27 found less sensitization in devices with smo
ather than textured interior surfaces, whereas Kumpati and
oworkers28 found no difference.
We conclude that sensitization after LVAD placement as
ridge to transplantation becomes increasingly prevalent as
ength of support increases. Perioperative transfusion of
eukocyte-filtered cellular blood products does not appear to
orsen the incidence or the degree of HLA sensitization in
atients who receive LVADs as a bridge to transplantation.
voiding perioperative transfusions does not protect from
nd may even worsen allosensitization before transplanta-
ion. On the contrary, transfusion may be associated with
ess sensitization, possibly through immunosuppressive
echanisms. In this era of leukocyte filtration of cellular
lood products, other factors may be more important con-
ributors to sensitization of LVAD recipients. Transplanta-
ion before sensitization occurs will alleviate the potential
motional and physical toll on LVAD recipients by reduc-
ng time waiting and potential LVAD complications, which
upports current organ allocation policy. Further study may
uggest ways that transfusions can be used as a tool to
revent HLA sensitization and improve outcomes in this
hallenging patient population.
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